This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
by Zacks Equity Research
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
by Zacks Equity Research
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
by Zacks Equity Research
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
by Zacks Equity Research
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
by Zacks Equity Research
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
by Zacks Equity Research
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
by Zacks Equity Research
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
by Zacks Equity Research
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
by Zacks Equity Research
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
by Zacks Equity Research
United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
by Zacks Equity Research
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
by Zacks Equity Research
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Company News for Jun 30, 2025
by Zacks Equity Research
Companies In The News Are: NKE, CNXC, CRMD, CORZ, CRWV.